Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates 
Barclays Downgrades Siemens Energy as Valuation Seen Near Peak 
SpaceX Stock Draws Bullish Wall Street Coverage Ahead of Nasdaq-100 Inclusion 
Mizuho’s Top U.S. Industrials Stocks: Why Corteva and Stanley Black & Decker Stand Out 
Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results 
Bernstein Names IAG, Ryanair as Top European Airline Stocks Ahead of Earnings 
Samsung Chairman Lee Jae-yong Expected to Meet Nvidia CEO Jensen Huang on AI and Chip Partnership 
BHP Faces Port Hedland Strike Threat as Iron Ore Export Risks Grow 
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia 
Lockheed Martin, Rheinmetall Plan First ATACMS Missile Production in Germany 
Wolfspeed Sues Navitas Over GaN and SiC Patent Infringement 
SK Hynix’s $28B U.S. IPO Draws Strong Demand as AI Chip Boom Fuels Investor Interest 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
Telenor to Buy Controlling Stake in Bahnhof in $630 Million Broadband Deal 
Chinese Chip Stocks Jump as Apple Reportedly Tests CXMT Memory Chips for China Devices 
SK Hynix’s $28 Billion U.S. Share Sale Draws Massive Demand Amid AI Chip Boom 
YARDLEY, Pa., May 07, 2018 -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will release financial results for the first quarter 2018, before market open on Monday, May 14, 2018.
Members of the Company’s leadership team will host a conference call to discuss financial results and corporate updates, including the retail availability of XHANCETM that commenced in early April 2018. The call is scheduled to start at 8:00 a.m. Eastern Time on Monday, May 14, 2018.
To participate on the conference call, please dial (866) 916-4761 from the U.S. or +1 (409) 216-6496 from outside the U.S. In addition, following the completion of the call, a telephone replay will be accessible until May 21, 2018 by dialing (855) 859-2056 from the U.S. or +1 (404) 537-3406 from outside the U.S. and entering conference ID # 6968158. A simultaneous webcast of the call and presentation can be accessed by visiting the Investors section of Optinose’s website at www.optinose.com. In addition, a replay of the webcast will be available on the Company website for 60 days following the event.
About Optinose
Optinose is a global specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists. Optinose has offices in the U.S., the U.K. and Norway. To learn more, please visit www.optinose.com or follow us on Twitter and LinkedIn.
Optinose Investor Contact
Jonathan Neely
[email protected]
267.521.0531
